The effects of modifying in vivo cytochrome P450 3A (CYP3A) activity on etoricoxib pharmacokinetics and of etoricoxib administration on CYP3A activity.

MLA

Agrawal, Nancy G. B., et al. “The Effects of Modifying in Vivo Cytochrome P450 3A (CYP3A) Activity on Etoricoxib Pharmacokinetics and of Etoricoxib Administration on CYP3A Activity.” Journal of Clinical Pharmacology, vol. 44, no. 10, Oct. 2004, pp. 1125–31. EBSCOhost, https://doi.org/10.1177/0091270004268129.

APA

Agrawal, N. G. B., Matthews, C. Z., Mazenko, R. S., Woolf, E. J., Porras, A. G., Chen, X., Miller, J. L., Michiels, N., Wehling, M., Schultz, A., Gottlieb, A. B., Kraft, W. K., Greenberg, H. E., Waldman, S. A., Curtis, S. P., & Gottesdiener, K. M. (2004). The effects of modifying in vivo cytochrome P450 3A (CYP3A) activity on etoricoxib pharmacokinetics and of etoricoxib administration on CYP3A activity. Journal of Clinical Pharmacology, 44(10), 1125–1131. https://doi.org/10.1177/0091270004268129

Chicago

Agrawal, Nancy G B, Catherine Z Matthews, Ralph S Mazenko, Eric J Woolf, Arturo G Porras, Xun Chen, Jutta L Miller, et al. 2004. “The Effects of Modifying in Vivo Cytochrome P450 3A (CYP3A) Activity on Etoricoxib Pharmacokinetics and of Etoricoxib Administration on CYP3A Activity.” Journal of Clinical Pharmacology 44 (10): 1125–31. doi:10.1177/0091270004268129.